Ken Griffin Volitionrx LTD Transaction History

Citadel Advisors LLC

  • $559 Billion
  • Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Volitionrx LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 4,400 shares of VNRX stock, worth $2,552. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,400
Previous 20,400 78.43%
Holding current value
$2,552
Previous $12,000 83.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$0.56 - $0.88 $38,187 - $60,008
68,192 New
68,192 $40,000
Q2 2024

Aug 14, 2024
BUY
$0.59 - $0.91 $17 - $26
29 New
29 $0
Q2 2023

Aug 14, 2023
SELL
$1.39 - $2.02 $19,461 - $28,282
-14,001 Reduced 68.91%
6,317 $8,000
Q1 2023

May 15, 2023
SELL
$1.54 - $2.68 $94,920 - $165,187
-61,637 Reduced 75.21%
20,318 $38,000
Q4 2022

Feb 14, 2023
SELL
$1.39 - $2.6 $30,471 - $56,997
-21,922 Reduced 21.1%
81,955 $199,000
Q3 2022

Nov 14, 2022
BUY
$1.36 - $2.38 $106,353 - $186,118
78,201 Added 304.57%
103,877 $141,000
Q2 2022

Aug 15, 2022
SELL
$1.96 - $3.05 $905 - $1,409
-462 Reduced 1.77%
25,676 $53,000
Q1 2022

May 16, 2022
BUY
$2.41 - $3.24 $36,632 - $49,248
15,200 Added 138.97%
26,138 $79,000
Q4 2021

Feb 14, 2022
SELL
$3.02 - $4.13 $24,573 - $33,605
-8,137 Reduced 42.66%
10,938 $34,000
Q3 2021

Nov 15, 2021
BUY
$2.98 - $3.48 $56,843 - $66,381
19,075 New
19,075 $59,000
Q3 2020

Nov 16, 2020
SELL
$2.94 - $4.05 $37,852 - $52,143
-12,875 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$2.89 - $4.32 $37,208 - $55,620
12,875 New
12,875 $50,000

Others Institutions Holding VNRX

# of Institutions
31
Shares Held
18.9M
Call Options Held
21K
Put Options Held
0
View Full List

About VOLITIONRX LTD

VNRX Quotes by TradingView
  • Ticker VNRX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 57,297,000
  • Market Cap $33.2M
  • Description
  • VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating sampl...
More about VNRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email